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Background/Introduction
The role of adjuvant chemotherapy for stage I lung can-
cer is unknown. Some Japanese trials demonstrated that
tegaful-uracil chemotherapy improved the prognosis of
stage I lung cancer over 2 cm.
Aims/Objectives
The purpose of this study is to determine the signifi-
cance of the maximum standardized uptake value (SUV-
max) on F-18-fluorodeoxyglucose positron emission
tomography/computed tomography (FDG-PET/CT)
images to postoperative adjuvant chemotherapy for early
lung adenocarcinoma.
Method
We reviewed 174 consecutive patients with completely
resected pathological T1b-2aN0M0 lung adenocarcinoma
between January 2006 and March 2011, and assessed
recurrence-free interval and overall survival based on
SUVmax values derived from preoperative FDG-PET/CT
images. All patients were assessed by FDG-PET/CT
before surgery
Results
Ninety patients received adjuvant chemotherapy and 84 did
not. Patients given adjuvant chemotherapy were older, but
had the lower T status tumor than patients who were not
(both, p < 0.001). Adjuvant chemotherapy conferred bene-
fits upon recurrence-free interval and overall survival com-
pared with observation (p = 0.007 and p = 0.004,
respectively). Multivariate Cox proportional hazard analyses
revealed SUVmax as an independent prognostic factor for
recurrence-free interval (hazard ratio 8.03, p < 0.001).
Recurrence-free interval and overall survival were sig-
nificantly longer for patients who received adjuvant
chemotherapy compared with those who did not in the
group with SUVmax ≤ 2.6 (p < 0.001 and p < 0.001, respec-
tively). However, recurrence-free interval and overall survi-
val did not significantly differ between such patients in the
group with SUVmax < 2.6 (p = 0.421 and p = 0.452,
respectively).
Discussion/Conclusion
Preoperative SUVmax on FDG-PET/CT images reflected
the efficacy of postoperative adjuvant chemotherapy in
patients with pathological T1b-2aN0M0 lung adenocar-
cinoma. Indications of adjuvant chemotherapy for eraly
lung adenocarcinoma might be more precisely deter-
mined using SUVmax on FDG-PET/CT images together
with tumor size.
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